scispace - formally typeset
Journal ArticleDOI

Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography

TLDR
Genetic amniocentesis should be considered in women of any age when second-trimester ultrasonography reveals the presence of one or more of the following: fetal structural malformations, short femur (determined by biparietal diameter-to-femur length ratio), combination of short Femur and humerus, abnormal nuchal fold thickening, echogenic bowel, or short ear length.
About
This article is published in American Journal of Obstetrics and Gynecology.The article was published on 1995-03-01. It has received 163 citations till now. The article focuses on the topics: Trisomy & Pyelectasis.

read more

Citations
More filters
Journal ArticleDOI

Screening for fetal aneuploidies at 11 to 13 weeks

TL;DR: Improvement in the performance of first‐trimester screening can be achieved by firstly, inclusion in the ultrasound examination assessment of the nasal bone and flow in the ductus venosus, hepatic artery and across the tricuspid valve, and secondly, carrying out the biochemical test at 9 to 10 weeks and the ultrasound scan at 12 weeks.
Journal ArticleDOI

Antenatal screening for Down's syndrome

TL;DR: Methods of screening need to be fully evaluated before being introduced into routine clinical practice, including choosing markers for which there is sufficient scientific evidence of efficacy, quantifying performance in terms of detection and false positive rates, and establishing methods of monitoring performance.
Journal ArticleDOI

Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy.

TL;DR: This work aims to determine whether sonographic "markers" are associated with fetal Down syndrome during the second trimester and to estimate the degree of risk of individual markers using likelihood ratios.
Journal ArticleDOI

Meta‐analysis of second‐trimester markers for trisomy 21

TL;DR: To summarize by meta‐analysis the accumulated data on the screening performance of second‐trimester sonographic markers for fetal trisomy 21 shows clear trends in maternal morbidity and mortality during the second trimester.
Journal ArticleDOI

Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases

TL;DR: A method of individual risk assessment for fetal Down's syndrome based on maternal age and second‐trimester ultrasound findings is described and tested.
References
More filters
Journal ArticleDOI

Sonographic identification of second-trimester fetuses with Down's syndrome.

TL;DR: Fetuses with Down's syndrome are more likely than normal fetuses to have a thickened nuchal skin fold and relatively short femurs on ultrasound examination in the second trimester.
Journal ArticleDOI

A sonographic screening method for Down syndrome

TL;DR: The biparietal diameter/femur length ratio may prove superior to current Down syndrome screening methods and, as a third independent variable, may significantly enhance the sensitivity and specificity of combined maternal age/maternal serum alpha-fetoprotein screening modalities.
Journal ArticleDOI

Prenatal sonographic findings of Down syndrome: review of 94 cases.

TL;DR: Prenatal ultrasound findings were reviewed in 94 consecutive fetuses with proved Down syndrome (trisomy 21) during a 6-year period at a single institution and one or more abnormalities were found in 31 fetuses (33%) as mentioned in this paper.
Journal ArticleDOI

Humerus and femur length shortening in the detection of Down's syndrome

TL;DR: Prenatal ultrasonographic detection of short humerus to short femur, or both significantly increase the risk of Down's syndrome; this information may be useful in screening programs.
Journal ArticleDOI

Humeral shortening in second-trimester fetuses with Down syndrome.

TL;DR: In this article, the relationship between humeral length and biparietal diameter was evaluated in 400 normal second-trimester controls and in 24 consecutive Down syndrome fetuses (14-20 weeks) undergoing amniocentesis for advanced maternal age or low maternal serum alpha-fetoprotein (MSAFP).
Related Papers (5)